Zoetis Inc. operates in the healthcare sector within the biotechnology and pharmaceutical industry focused on veterinary medicine, developing and commercializing medicines, vaccines and diagnostic solutions for animal health.

The company specializes exclusively in products for livestock and companion animals, supplying veterinary clinics, livestock producers, agribusiness companies and distributors across global markets.

Its main areas of activity include:

• Veterinary vaccines designed to prevent infectious diseases in livestock and pets.
• Pharmaceutical treatments such as antiparasitics, antibiotics, dermatology therapies and anti-inflammatory medicines.
• Diagnostic products and laboratory testing services used in veterinary practices.
• Animal health monitoring technologies, including digital tools and data solutions for livestock management.

Zoetis serves multiple animal health segments, including cattle, poultry, swine, equine, aquaculture and companion animals such as dogs and cats.

The company operates globally, with significant commercial and research presence in North America, Europe, Latin America and Asia, supporting veterinary and agricultural markets worldwide.

Industry dynamics affecting Zoetis include the expansion of the companion animal market, global demand for animal protein, biotechnology innovation in veterinary medicine, regulatory standards related to animal health and competition from companies such as Elanco, Boehringer Ingelheim and Merck Animal Health.

Shares of Zoetis Inc. trade on the New York Stock Exchange (NYSE) under the ticker ZTS.

History and Development

Zoetis Inc. was established as an independent company in 2012 following the spin-off of Pfizer’s animal health division, which had developed veterinary medicines for decades.

Although the company became independent in 2012, its origins trace back to the early twentieth century, when Pfizer began investing in research related to veterinary pharmaceuticals.

In 2013, Zoetis completed its initial public offering (IPO) on the New York Stock Exchange, becoming one of the largest healthcare IPOs of that period.

During the following decade, the company expanded through investments in veterinary diagnostics, digital monitoring technologies and specialized therapies for companion animals.

In recent years, Zoetis has continued strengthening its manufacturing capacity, research infrastructure and biotechnology portfolio, focusing on innovative treatments, vaccines and diagnostic solutions for global animal health markets.